Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness

Ruffini,Federica; Tentori,Lucio; Dorio,Annalisa   Susanna; Arcelli,Diego; D'Amati,Giulia; D'Atri,Stefania; Graziani,Grazia; Lacal,Pedro  Miguel

doi:10.3892/or.2013.2791

Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness

Authors:
- Federica Ruffini
- Lucio Tentori
- Annalisa Susanna Dorio
- Diego Arcelli
- Giulia D'Amati
- Stefania D'Atri
- Grazia Graziani
- Pedro Miguel Lacal
View Affiliations

Affiliations: Laboratory of Molecular Oncology, ‘Istituto Dermopatico dell'Immacolata’- IRCCS, Rome, Italy, Department of System Medicine, University of Rome ‘Tor Vergata’, Rome, Italy, Laboratory of Immunology, Regina Elena National Cancer Institute, Rome, Italy, Department of Radiological, Oncological and Pathological Sciences, Sapienza University, Rome, Italy
Published online on: October 10, 2013 https://doi.org/10.3892/or.2013.2791
Pages: 2887-2896

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The molecular mechanisms responsible for the elevated metastatic potential of malignant melanoma are still not fully understood. In order to shed light on the molecules involved in the acquisition by melanoma of a highly aggressive phenotype, we compared the gene expression profiles of two cell clones derived from the human cutaneous metastatic melanoma cell line M14: a highly invasive clone (M14C2/MK18) and a clone (M14C2/C4) with low ability to invade the extracellular matrix (ECM). The highly invasive phenotype of M14C2/MK18 cells was correlated with overexpression of neuropilin-1, activation of a vascular endothelial growth factor (VEGF)-A/VEGFR-2 autocrine loop and secretion of matrix metalloprotease-2. Moreover, in an in vivo murine model, M14C2/MK18 cells displayed a higher growth rate as compared with M14C2/C4 cells, even though in vitro both clones possessed comparable proliferative potential. Microarray analysis in M14C2/MK18 cells showed a strong upregulation of platelet-derived growth factor (PDGF)-C, a cytokine that contributes to angiogenesis, and downregulation of calpain-3, a calcium-dependent thiol-protease that regulates specific signalling cascade components. Inhibition of PDGF-C with a specific antibody resulted in a significant decrease in ECM invasion by M14C2/MK18 cells, confirming the involvement of PDGF-C in melanoma cell invasiveness. Moreover, the PDGF-C transcript was found to be upregulated in a high percentage of human melanoma cell lines (17/20), whereas only low PDGF-C levels were detected in a few melanocytic cultures (2/6). By contrast, inhibition of calpain-3 activity in M14C2/C4 control cells, using a specific chemical inhibitor, markedly increased ECM invasion, strongly suggesting that downregulation of calpain-3 plays a role in the acquisition of a highly invasive phenotype. The results indicate that PDGF-C upregulation and calpain-3 downregulation are involved in the aggressiveness of malignant melanoma and suggest that modulators of these proteins or their downstream effectors may synergise with VEGF‑A therapies in combating tumour-associated angiogenesis and melanoma spread.

View Figures

View References

1	Berwick M, Erdei E and Hay J: Melanoma epidemiology and public health. Dermatol Clin. 27:205–214. 2009. View Article : Google Scholar
2	Becker D, Mihm MC, Hewitt SM, Sondak VK, Fountain JW and Thurin M: Markers and tissue resources for melanoma: meeting report. Cancer Res. 66:10652–10657. 2006.PubMed/NCBI
3	Nazarian RM, Prieto VG, Elder DE and Duncan LM: Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol. 37:41–47. 2010. View Article : Google Scholar : PubMed/NCBI
4	Lacal PM, Failla CM, Pagani E, et al: Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol. 115:1000–1007. 2000. View Article : Google Scholar : PubMed/NCBI
5	Lacal PM, Ruffini F, Pagani E and D’Atri S: An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol. 27:1625–1632. 2005.PubMed/NCBI
6	Schietroma C, Cianfarani F, Lacal PM, et al: Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer. 98:789–797. 2003. View Article : Google Scholar : PubMed/NCBI
7	Ruffini F, Failla CM, Orecchia A, et al: Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression. Br J Dermatol. 164:1061–1070. 2011. View Article : Google Scholar : PubMed/NCBI
8	Hennequin LF, Thomas AP, Johnstone C, et al: Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem. 42:5369–5389. 1999. View Article : Google Scholar : PubMed/NCBI
9	Sasaki T, Kishi M, Saito M, et al: Inhibitory effect of di- and tripeptidyl aldehydes on calpains and cathepsins. J Enzyme Inhib. 3:195–201. 1990. View Article : Google Scholar : PubMed/NCBI
10	Lacal PM, Morea V, Ruffini F, et al: Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide. Eur J Cancer. 44:1914–1921. 2008. View Article : Google Scholar : PubMed/NCBI
11	Lacal PM, Tentori L, Muzi A, et al: Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells. Int J Oncol. 34:861–872. 2009.PubMed/NCBI
12	Ruffini F, D’Atri S and Lacal PM: Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2 dependent and independent mechanisms. Int J Oncol. 43:297–306. 2013.
13	Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 103:1237–1241. 1999.PubMed/NCBI
14	Wang Z, Juttermann R and Soloway PD: TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem. 275:26411–26415. 2000. View Article : Google Scholar
15	Hoek KS, Schlegel NC, Eichhoff OM, et al: Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res. 21:665–676. 2008. View Article : Google Scholar
16	Fredriksson L, Ehnman M, Fieber C and Eriksson U: Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator. J Biol Chem. 280:26856–26862. 2005. View Article : Google Scholar : PubMed/NCBI
17	Li X, Pontén A, Aase K, et al: PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol. 2:302–309. 2000. View Article : Google Scholar
18	Gilbertson DG, Duff ME, West JW, et al: Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem. 276:27406–27414. 2001.PubMed/NCBI
19	Fredriksson L, Li H, Fieber C, Li X and Eriksson U: Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J. 23:3793–3802. 2004.
20	Cao R, Bråkenhielm E, Li X, et al: Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-αα and -αβ receptors. FASEB J. 16:1575–1583. 2002.PubMed/NCBI
21	Dimmeler S: Platelet-derived growth factor CC - a clinically useful angiogenic factor at last? N Engl J Med. 352:1815–1816. 2005.PubMed/NCBI
22	Li X, Tjwa M, Moons L, et al: Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest. 115:118–127. 2005. View Article : Google Scholar : PubMed/NCBI
23	Anderberg C, Li H, Fredriksson L, et al: Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer associated fibroblasts. Cancer Res. 69:369–378. 2009.PubMed/NCBI
24	Hurst NJ Jr, Najy AJ, Ustach CV, Movilla L and Kim HR: Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression. Biochem J. 441:909–918. 2012. View Article : Google Scholar : PubMed/NCBI
25	Zwerner JP and May WA: PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene. 20:626–633. 2001. View Article : Google Scholar : PubMed/NCBI
26	Zwerner JP and May WA: Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines. Oncogene. 21:3847–3854. 2002. View Article : Google Scholar : PubMed/NCBI
27	Andrae J, Molander C, Smits A, Funa K and Nistér M: Platelet-derived growth factor-B and -C and active alpha-receptors in medulloblastoma cells. Biochem Biophys Res Commun. 296:604–611. 2002. View Article : Google Scholar : PubMed/NCBI
28	Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA and Giese NA: Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumours. Cancer Res. 62:3729–3735. 2002.
29	Yamano Y, Uzawa K, Saito K, et al: Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. Int J Cancer. 126:437–449. 2010. View Article : Google Scholar : PubMed/NCBI
30	Crawford Y, Kasman I, Yu L, et al: PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 15:21–34. 2009. View Article : Google Scholar : PubMed/NCBI
31	Li X, Kumar A, Zhang F, Lee C, Li Y, Tang Z and Arjuna P: VEGF-independent angiogenic pathways induced by PDGF-C. Oncotarget. 1:309–314. 2010.PubMed/NCBI
32	di Tomaso E, London N, Fuja D, et al: PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS One. 4:e51232009.PubMed/NCBI
33	Ono Y, Ojima K, Torii F, et al: Skeletal muscle-specific calpain is an intracellular Na⁺-dependent protease. J Biol Chem. 285:22986–22998. 2010. View Article : Google Scholar : PubMed/NCBI
34	Storr SJ, Carragher NO, Frame MC, Parr T and Martin SG: The calpain system and cancer. Nat Rev Cancer. 11:364–374. 2011. View Article : Google Scholar : PubMed/NCBI
35	Moretti D, Del Bello B, Cosci E, Biagioli M, Miracco C and Maellaro E: Novel variants of muscle calpain 3 identified in human melanoma cells: cisplatin-induced changes in vitro and differential expression in melanocytic lesions. Carcinogenesis. 30:960–967. 2009. View Article : Google Scholar
36	Hodgkinson CA, Moore KJ, Nakayama A, Steingrímsson E, Copeland NG, Jenkins NA and Arnheiter H: Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell. 74:395–404. 1993. View Article : Google Scholar : PubMed/NCBI
37	Vachtenheim J, Novotna H and Ghanem G: Transcriptional repression of the microphthalmia gene in melanoma cells correlates with the unresponsiveness of target genes to ectopic microphthalmia-associated transcription factor. J Invest Dermatol. 117:1505–1511. 2001. View Article : Google Scholar
38	McGill GG, Horstmann M, Widlund HR, et al: Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell. 109:707–718. 2002. View Article : Google Scholar : PubMed/NCBI
39	Du J, Widlund HR, Horstmann MA, et al: Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell. 6:565–576. 2004. View Article : Google Scholar : PubMed/NCBI
40	Steingrimsson E, Copeland NG and Jenkins NA: Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet. 38:365–411. 2004. View Article : Google Scholar
41	Carreira S, Goodall J, Aksan I, et al: Mitf cooperates with Rb1 and activates p21^Cip1 expression to regulate cell cycle progression. Nature. 433:764–769. 2005. View Article : Google Scholar : PubMed/NCBI
42	Loercher AE, Tank EM, Delston RB and Harbour JW: MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol. 168:35–40. 2005. View Article : Google Scholar : PubMed/NCBI
43	Levy C, Khaled M and Fisher DE: MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 12:406–414. 2006. View Article : Google Scholar : PubMed/NCBI
44	Wu M, Hemesath TJ, Takemoto CM, et al: c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 14:301–312. 2000.PubMed/NCBI
45	Levy C, Sonnenblick A and Razin E: Role played by microphthalmia transcription factor phosphorylation and its Zip domain in its transcriptional inhibition by PIAS3. Mol Cell Biol. 23:9073–9080. 2003. View Article : Google Scholar : PubMed/NCBI
46	De Morrée A, Hulsik DL, Impagliazzo A, et al: Calpain 3 is a rapid-action, unidirectional proteolytic switch central to muscle remodelling. PLoS One. 5:e119402010.PubMed/NCBI